MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Novel target anti-lung cancer siRNA therapies, treatment drugs

Korea Health Industry Development Institute
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority

Mechanism of action

AIMP2 (Aminoacyl-tRNA synthetase-interacting multifunctional protein 2) Previously known as p38/JTV-1_AIMP2-DX2Splicing variant of AIMP2 that inactivates normal activity of AIMP2

Full description

. Unique Merits of AIMP2 Targeting Anticancer Drugs

1.     Previously Unexplored Target with Novel Working Mechanisms

             (Global Initiatives in R&D and IP Position)

2.     Generation of Tumorigenic Variant of AIMP2 Is  Major Cause for Lung Caner

(Cancer-specific Target Available)

3.     Suppression of AIMP2-DX2 Proven Effective against Lung Cancer

4.     Small Chemical and siRNA Drug Candidates Are Available

5.     Patents for Material and Usage Are Established Worldwide

 

. Our Products to develop

•      Si-DX2 therapy -

–      Specific AIMP2-DX2 inhibitor

–      Aerosol inhalation administration

–      Low toxicity and high efficiency of delivery

•      Diagnostics

–      Immuno histochemical Method

–      QPCR AIMP2DX2 detection

–      RISH detection system

–      AIMP2 targeting small chemical drugs

–      4 drug candidates identified

Animal efficacy show

Development status

Early Stage

Patent information

 

AIMP2 Patent Portfolio:

Country

Patent or Patent Application Title

Patent or Patent Application Number

United States

Method for treating cancer using p38/JTV-1 and method for screening pharmaceutical composition for treating cancer

US 2004/0175375

10/463,676

18 Jun 03

 

Europe

Medical use of p38/JTV-1

EP 1454628

09 Sep 03

Japan

Pharmaceutical composition for cancer therapy with p38/JTV-1 as active ingredient and method for screening the composition

JP 2003-377932

07 Nov. 2003

 

Korea

Pharmaceutical composition for treatment of cancer containing p38/JTV-1 as effective component and screening method of pharmaceutical composition for treatment of cancer

KR 2003-18424

25th  Mar 2003

 

 

 

 

AIMP2-DX2 Patent Portfolio:

Country

Patent Application Title

Patent Application Number

Korea

Use of AIMP2-DX2 for the diagnosis and treatment of cancer

KR10-2005-0110946

18th March, 2005

Korea

Use of AIMP2-DX2 for the diagnosis and treatment of cancer

KR10-2006-0047831

26th May, 2006

International (PCT)

Use of AIMP2-DX2 for the diagnosis and treatment of cancer

PCT/KR2005/003924

18th March, 2005

United States

AIMP2-DX2 and its uses

US 11/264,725

 1st   Nov. 2005

Europe

AIMP2-DX2 and its uses

EP05819055.4

4th April, 2007

China

AIMP2-DX2 and its uses

CN200580037802.9

 30th April, 2007

Japan

AIMP2-DX2 and its uses

JP2007-542907

24th May, 2007

 

Type of business relationship sought

1. Overseas Licensing Opportunity

2. Seeking potential corporate partners

Licensing contact

Yong U Kim
Researcher
Technology Business Center

Contact directly

Company details

Korea Health Industry Development Institute

KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
EthyPharm
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us